Syros Pharmaceuticals (NASDAQ:SYRS) vs. Cyclacel Pharmaceuticals (NASDAQ:BGMS) Critical Survey

Syros Pharmaceuticals (NASDAQ:SYRS) and Cyclacel Pharmaceuticals (NASDAQ:BGMS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations and earnings.

Risk & Volatility

Syros Pharmaceuticals has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500. Comparatively, Cyclacel Pharmaceuticals has a beta of -0.45, meaning that its stock price is 145% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings for Syros Pharmaceuticals and Cyclacel Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syros Pharmaceuticals	0	0	0	0	0.00
Cyclacel Pharmaceuticals	1	0	0	0	1.00

Valuation and Earnings

This table compares Syros Pharmaceuticals and Cyclacel Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syros Pharmaceuticals	$386,000.00	0.01	-$164.57 million	($3.03)	0.00
Cyclacel Pharmaceuticals	$40,000.00	116.38	-$11.21 million	($81.45)	-0.01

Cyclacel Pharmaceuticals has lower revenue, but higher earnings than Syros Pharmaceuticals. Cyclacel Pharmaceuticals is trading at a lower price-to-earnings ratio than Syros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

91.5% of Syros Pharmaceuticals shares are held by institutional investors. Comparatively, 23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. 12.3% of Syros Pharmaceuticals shares are held by insiders. Comparatively, 51.2% of Cyclacel Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Syros Pharmaceuticals and Cyclacel Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Syros Pharmaceuticals	N/A	-3,369.56%	-97.04%
Cyclacel Pharmaceuticals	N/A	-187.37%	-106.68%

Summary

Syros Pharmaceuticals beats Cyclacel Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company’s development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing’s disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.